Taysha Gene Therapies, Inc. (TSHA)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch TSHA
See up to 3 months of TSHA. The 7-day demo opens the 1M and 3M ranges and puts TSHA on your watchlist.
Start 7-day demoLatest TSHA insider trades
About Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. is an SEC registrant, filing under CIK 0001806310, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
TSHA Form 4 activity by transaction type, last 90 days
No Form 4 activity for TSHA in the last 90 days.
TSHA insider transactions (Form 4)
4518 Form 4 filings on record, the earliest from Jun 2, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $6.24 footnote F2 | $1.25M | |
| ||||||
| John A. Stalfort III | Grant or award | Common Stock | 21,335 footnote F1 | $0.00 | - | |
| John A. Stalfort III | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| ||||||
| Phillip B. Donenberg | Grant or award | Common Stock | 21,335 footnote F1 | $0.00 | - | |
| Phillip B. Donenberg | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| ||||||
| Alison S. Long | Grant or award | Common Stock | 21,335 footnote F1 | $0.00 | - | |
| Alison S. Long | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| ||||||
 Laura Sepp-Lorenzino | Grant or award | Common Stock | 21,335 footnote F1 | $0.00 | - | |
| Laura Sepp-Lorenzino | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| ||||||
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 19,021 | $1.71 | $33K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $4.46 footnote F2 | $892K | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 19,021 | $0.00 | - | |
| ||||||
| Kamran Alam - Officer | Open-market sale | Common Stock | 1,655 footnote F1 | $4.52 | $7K | |
| ||||||
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 89,132 footnote F1 | $4.75 footnote F2 | $423K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 26,918 footnote F1 | $4.61 footnote F3 | $124K | |
| ||||||
 Sean P. Nolan - Officer | Open-market sale | Common Stock | 136,789 footnote F1 | $4.75 footnote F2 | $650K | |
| Sean P. Nolan - Officer | Open-market sale | Common Stock | 41,312 footnote F1 | $4.61 footnote F3 | $190K | |
| ||||||
| Kamran Alam - Officer | Open-market sale | Common Stock | 78,968 footnote F1 | $4.75 footnote F2 | $375K | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 23,849 footnote F1 | $4.61 footnote F3 | $110K | |
| ||||||
| Kamran Alam - Officer | Grant or award | Common Stock | 359,000 footnote F1 | $0.00 | - | |
| Kamran Alam - Officer | Grant or award | Employee Stock Option (right to buy) | 231,000 | $0.00 | - | |
| ||||||
| Sean P. Nolan - Officer | Grant or award | Common Stock | 1,008,000 footnote F1 | $0.00 | - | |
| Sean P. Nolan - Officer | Grant or award | Employee Stock Option (right to buy) | 648,000 | $0.00 | - | |
| ||||||
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 111,324 | $0.70 | $78K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 88,676 | $1.71 | $152K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $4.71 footnote F2 | $942K | |
| Sukumar Nagendran - Officer | Grant or award | Common Stock | 427,000 footnote F3 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 111,324 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 88,676 | $0.00 | - | |
| Sukumar Nagendran - Officer | Grant or award | Employee Stock Option (right to buy) | 274,000 | $0.00 | - | |
| ||||||
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 70,172 | $0.70 | $49K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 39,953 | $1.71 | $68K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 110,125 | $4.75 footnote F1 | $523K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 260,047 | $1.71 | $445K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 260,047 | $4.51 footnote F2 | $1.17M | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 70,172 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 39,953 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 260,047 | $0.00 | - | |
| ||||||
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 41,150 | $0.70 | $29K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $3.23 | $646K | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 41,150 | $0.00 | - | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 54,491 | $2.85 | $155K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 57,054 | $2.85 | $163K | |
| Phillip B. Donenberg | Grant or award | Common Stock | 56,623 | $0.00 | - | |
| Phillip B. Donenberg | Grant or award | Stock Option (right to buy) | 113,246 | $0.00 | - | |
Item 2.02, 9.01
Item 1.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 5.07
Recent TSHA Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
TSHA insider trading FAQ
What is the latest insider trade for TSHA?
Taysha Gene Therapies, Inc. (TSHA) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-10. The full record for TSHA runs to 18 Form 4 filings, the earliest from 2025-06-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TSHA stock?
No insider purchases of TSHA were filed in the last 90 days.
How many insiders are selling TSHA stock?
No insider sales of TSHA were filed in the last 90 days. 15 sales are on record for this company.
Where can I see TSHA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TSHA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Sukumar Nagendran view on EDGAR
- - John A. Stalfort III view on EDGAR
- - Phillip B. Donenberg view on EDGAR
- - Alison S. Long view on EDGAR
- - Laura Sepp-Lorenzino view on EDGAR
- - Sukumar Nagendran view on EDGAR
- - Kamran Alam view on EDGAR
- - Sukumar Nagendran view on EDGAR
- - Sean P. Nolan view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where TSHA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TSHA with a 7-day demo
- TSHA on your watchlist
- Every TSHA Form 4 filing on record
- Up to 3 months of TSHA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
